Safety monitoring and information
Understand the ways we work to ensure medicines and medical devices remain as safe and effective as possible. Access information on product safety topics.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
What safety means
Safety is determined by weighing the known and potential risks, against the expected benefits when a therapeutic good is used as intended. While some risks are identified during the approval process, others may only become apparent after broader use.
The safety of therapeutic goods is a shared responsibility between regulators, sponsors, healthcare professionals and consumers.
How we monitor safety
We monitor safety through a range of different activities:
- Pre-market evaluation: Products must meet strict safety, quality and efficacy standards before being included in the Australian Register of Therapeutic Goods (ARTG).
- Post-market surveillance: We monitor products once they are on the market through adverse event reports, product testing, recalls and safety reviews.
- Adverse event reporting: Anyone can report adverse events or side effects, product defects or safety concerns. These reports help identify emerging risks and inform regulatory action.
- Product testing and investigations: Our laboratories test therapeutic goods to ensure they meet Australian standards and compare results with international benchmarks. See further information on our Product testing and investigations.
- Recalls and market actions: If a safety issue is identified, we may initiate recalls, issue safety alerts or require product corrections.
A key activity in safety monitoring is identifying patterns that emerge when problems are reported by sponsors, health professionals and consumers. An adverse event occurring does not necessarily mean that there is something wrong with a therapeutic good. However, each report helps to build a picture of the safety profile of a product. You can Report an adverse event or safety problem.
Latest alerts
-
Edgewell Personal Care Australia Pty Ltd is recalling all unexpired batches (nine in total) due to the potential for the lotions to become separated.
-
Gem Care Products Pty Ltd is recalling all unexpired batches (two in total) due to the potential for the lotions to become separated.
-
We are issuing an updated safety advisory regarding imported counterfeit unregistered melatonin products.
Latest articles
-
Upgrade of TGA’s internal database for medicine adverse events reports
The Adverse Event Management System (AEMS) has moved to the cloud, delivering improved system stability and security. -
The TGA releases compliance principles, reinforcing proactive and risk-based enforcement throughout 2026 and 2027
The TGA Compliance Principles 2026 and 2027 outlines our strategic approach to monitoring and enforcing regulatory compliance for the import, export, manufacture, supply and advertising of therapeutic goods in Australia. -
Conviction for unlawful supply and advertising of black salve products
An individual has been sentenced for unlawfully advertising and supplying black salve and bloodroot capsules, and for advertising other unapproved therapeutic goods to treat serious conditions such as anxiety.
Latest publications
-
Advisory Committee on Vaccines meeting statement 54
-
Communique from the 11th meeting of the Women's Health Products Working Group, 30 October 2025
-
Advisory Committee on Vaccines meeting statement 54
Open consultations
-
Survey on Digital Mental Health Tools
We are seeking input from stakeholders responsible for developing, deploying or supplying Digital Mental Health Tools (DMHT) to help us better understand these tools.